Tenax Therapeutics CEO Christopher Giordano acquires $20,087 in shares

Christopher Thomas Giordano, the CEO and Director of Tenax Therapeutics Inc. (NASDAQ:TENX), recently made a significant move in his personal investment portfolio. He acquired a total of $20,087 worth of common stock through two separate transactions. The first purchase came on September 11, 2026, where he bought 6,000 shares at a weighted average price of $1.875 per share.

These shares were acquired in multiple trades, costing between $1.87 and $1.88 each. Four days later, on September 15, Giordano increased his stake by adding 4,850 more shares, with a weighted average purchase price of $1.8221 per share, each trade costing between $1.82 and $1.83. This acquisition of shares, in addition to his existing stock options, underscores Mr. Giordano's confidence in Tenax Therapeutics despite recent financial challenges.